Pharmaceutical Manufacturing and Supply – Meclizine Hydrochloride Tablets

The contract involves the bulk supply of Meclizine Hydrochloride Tablets, USP, specifically requiring adherence to FDA regulations and current Good Manufacturing Practices (cGMP). The manufacturer must ensure that the production process meets stringent quality standards to guarantee the safety and efficacy of the pharmaceutical product. Additionally, appropriate packaging and labeling in compliance with regulatory guidelines are crucial components of the contract to assure proper identification and handling of the tablets. Issued by the Department of Defense through the Medical Supply Chain Pharmacy FSA, this subcontract aims to secure a reliable and compliant source of Meclizine Hydrochloride for medical use. The solicitation was posted on May 18, 2026, with a response deadline of May 26, 2026. It falls under the NAICS code 325412, which corresponds to pharmaceutical preparation manufacturing, highlighting the contract's focus on specialized pharmaceutical production. Specific locations for performance and points of contact are not provided, indicating potential flexibility or confidentiality in procurement details.